

**EIF4E2 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP1955a****Specification**

---

**EIF4E2 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [O60573](#)**EIF4E2 Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 9470

**Other Names**

Eukaryotic translation initiation factor 4E type 2, eIF-4E type 2, eIF4E type 2, Eukaryotic translation initiation factor 4E homologous protein, Eukaryotic translation initiation factor 4E-like 3, eIF4E-like protein 4E-LP, mRNA cap-binding protein 4EHP, mRNA cap-binding protein type 3, EIF4E2, EIF4EL3

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1955a](/product/products/AP1955a) was selected from the N-term region of human EIF4E2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**EIF4E2 Antibody (N-term) Blocking Peptide - Protein Information****Name** EIF4E2 {ECO:0000303|PubMed:15153109, ECO:0000312|HGNC:HGNC:3293}**Function**

Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation. Acts as a repressor of translation initiation (PubMed:[17368478](http://www.uniprot.org/citations/17368478), PubMed:[22751931](http://www.uniprot.org/citations/22751931), PubMed:[25624349](http://www.uniprot.org/citations/25624349), PubMed:[33581076](http://www.uniprot.org/citations/33581076), PubMed:[9582349](http://www.uniprot.org/citations/9582349)). In contrast to EIF4E, it is unable to bind eIF4G (EIF4G1, EIF4G2 or EIF4G3), suggesting that it acts by competing with EIF4E and block assembly of eIF4F at the cap (By similarity). In P-bodies, component of a complex that promotes miRNA-mediated translational repression (PubMed:[9582349](#)).

href="http://www.uniprot.org/citations/28487484" target="\_blank">28487484</a>). Involved in virus-induced host response by mediating miRNA MIR34A-induced translational silencing which controls IFNB1 production by a negative feedback mechanism (PubMed:<a href="http://www.uniprot.org/citations/28487484" target="\_blank">28487484</a>, PubMed:<a href="http://www.uniprot.org/citations/33581076" target="\_blank">33581076</a>).

**Cellular Location**

Cytoplasm. Cytoplasm, P-body

**EIF4E2 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**EIF4E2 Antibody (N-term) Blocking Peptide - Images****EIF4E2 Antibody (N-term) Blocking Peptide - Background**

EIF4E2 is expressed exclusively in the cytoplasm. This protein recognizes and binds the 7 methylguanosine containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.

**EIF4E2 Antibody (N-term) Blocking Peptide - References**

Rom, E., et al., J. Biol. Chem. 273(21):13104-13109 (1998). Mao, M., et al., Proc. Natl. Acad. Sci. U.S.A. 95(14):8175-8180 (1998). Tee, A.R., et al., FEBS Lett. 564 (1-2), 58-62 (2004) (): ().